Unraveling receptor-metabolite interactions in the human microbiome
AssigneeThe Rockefeller University
InventorSean Brady
Life of this patent
Estimating the term…
Abstract
The present invention relates to microorganisms and microbial metabolites derived therefrom that bind to a receptor and methods of use thereof
Claims22
A therapeutic composition comprising a microorganism and/or a microbial metabolite thereof, wherein the microorganism is selected from the group consisting of:
- Escherichia coli LF82, Enterococcus faecalis, Lactobacilhs plantarum, Faecalibacterium prauznitzii, Bifidobacterium longum, Bacteroides vulgatus, Ruminococcus gnavus, and any combination thereof.
(canceled)
(canceled)
A method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering a genetically engineered cell to the subject,
- wherein the genetically engineered cell expresses a metabolite that binds to a receptor, wherein the receptor is at least one receptor listed in FIG. 2B, FIG. 15, or any combination thereof.
A method of treating or preventing a disease or disorder associated with at least one microorganism and/or a microbial metabolite in a subject in need thereof, the method comprising modulating the level of the at least one microorganism and/or a microbial metabolite thereof in the subject,
- wherein the microorganism is selected from the group consisting of:
- Escherichia coli LF82, Enterococcus faecalis, Lactobacilhs plantarum, Faecalibacterium prauznitzii, Bifidobacterium longum, Bacteroides vulgatus, Ruminococcus gnavus, and any combination thereof.
Dependencies are inferred from the claim text.